To test whether JNK-BAD signaling is involved in the SH3BP3-promoted survival of AML cells, THP-1 cells were pre-treated with JNK agonist anisomycin, then infected with SH3BP5 shRNA. The gene discussed is BAD; the disease is acute myeloid leukemia.